The following is a summary of “Response to initial treatment with glucocorticoids in TAFRO syndrome and implications for ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

Pedraza-Cruz, P. , Varghese, M. , DiGiacomo, D. , Spencer, C. and Horani, O. (2025) Adrenal Crisis Secondary to Bilateral Adrenal Hemorrhage in a Patient with Hypercoagulable Disorder. Case Reports in ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

NEW HAVEN, Conn. - Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company with a market capitalization of $32.36 million, has initiated a Phase 2 clinical trial for RLYB212, a ...

Secondary endpoints included OS ... Myelosuppression consisting of anemia, neutropenia, and/or thrombocytopenia have been reported in patients treated with TALZENNA. In TALAPRO-2, Grade ≥3 anemia, ...

Rahul Banerjee, M.D., from the Fred Hutchinson Cancer Center in Seattle, and colleagues conducted a secondary pooled ... age 70 years or older, and thrombocytopenia. "Dexamethasone dose reductions ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Radium-223 re-treatment is safe for metastatic castration-resistant prostate cancer, per findings from the 2025 ASCO GU ...

Secondary (nonmendelian ... with a febrile illness. 13,17 Thrombocytopenia, anemia, and, to a lesser extent, neutropenia are common. Hemophagocytosis is not always present, particularly not ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...